Home/Pipeline/AGMB-447

AGMB-447

Idiopathic Pulmonary Fibrosis (IPF)

Phase 1bActive

Key Facts

Indication

Idiopathic Pulmonary Fibrosis (IPF)

Phase

Phase 1b

Status

Active

Company

Agomab Therapeutics

About Agomab Therapeutics

Agomab Therapeutics is a Belgium-based biotech focused on developing transformative treatments for fibrosis by modulating key growth factor pathways like TGFβ. The company successfully completed a $200 million IPO in February 2026, providing capital to advance its clinical pipeline, which includes both systemic and organ-restricted candidates. Its disciplined strategy targets established biology with innovative drug design to improve efficacy and safety profiles in a market with significant unmet need.

View full company profile

Therapeutic Areas

Fibrosis Immunology & Inflammatory Diseases

Other Idiopathic Pulmonary Fibrosis (IPF) Drugs

Drug	Company	Phase	Status
OATD-01	Molecure	Phase II	Active, recruiting
FP-020 (BMS-986235)	Foresee Pharmaceuticals	Phase 2	Active
Buloxibutid (C21)	Vicore Pharma	Phase 2b	Active, Now Enrolling
AP02	Avalyn Pharmaceuticals	Phase 2	Active
Gento-Fibrose Pulmonaire Program	Genoscience Pharma	Preclinical	Active
SM001 (alidornase/Tigerase)	SarcoMed USA	Research	Active
NLM-001	Nelum Pharma	Phase 1	Active
GNS-3545 (ROCK2 Inhibitor)	Genosco	Phase 1	Active
TG2 Inhibitor Program	Isterian Biotech	Preclinical	Active
Taladegib (ENV-101)	Endeavor BioMedicines	Phase 2b	Active
CAL101	Calluna Pharma	Phase 2	Active
NVP-13	Velvio	Pre-clinical	Active